Inhibitors and activation markers of the haemostatic system during hormone therapy: A comparative study of oral estradiol (2 mg)/ dydrogesterone and estradiol (2 mg)/ trimegestone

Thrombosis and Haemostasis

Volumn 100, Issue 2, 2008, Pages 253-260

  Norris, Lucy A ^a   Brosnan, Jeanette ^a   Bonnar, John ^a   Conard, Jacqueline ^b   Kluft, Cornelius ^c   Hellgren, Margareta ^d  

^a ST JAMES S HOSPITAL   (Ireland)

^b HÔTEL DIEU   (France)

^c TNO   (Netherlands)

^d SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Haemostasis; Hormones; Venous thrombosis

Indexed keywords

ACTIVATED PROTEIN C; ANTIPLASMIN; ANTITHROMBIN; BLOOD CLOTTING FACTOR 5 LEIDEN; DYDROGESTERONE PLUS ESTRADIOL; ESTRADIOL PLUS TRIMEGESTONE; ESTROGEN DERIVATIVE; PLASMIN; PROTEIN S; PROTHROMBIN;

ADULT; AGED; ARTICLE; BLOOD CLOTTING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG INHIBITION; FEMALE; FIBRINOLYSIS; GENE MUTATION; HORMONAL THERAPY; HUMAN; MEDICAL ASSESSMENT; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; ADULT; AGED; BLOOD COAGULATION TESTS; DYDROGESTERONE; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FACTOR V; FEMALE; FIBRINOLYSIS; HEMOSTASIS; HUMANS; MIDDLE AGED; PROGESTINS; PROMEGESTONE; PROTEIN C; PROTEIN S; RISK FACTORS; VENOUS THROMBOSIS;

EID: 48949106217     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH07-12-0746     Document Type: Article

References (41)

1. Hulley S, Grady D, Bush T. Randomised trial of estrogen plus progestin for secondary prevention of coronary heart disease in post menopausal women. Heart and Estrogen/Progestin Replacement therapy. J Am Med Assoc 1998; 280: 605-613.
2. Writing group for the Women's Health Initiative. Risks and benefits of estrogen plus progestin in healthy post menopausal women: Principal results from the Women's Health Initiative Randomised Controlled Trial. J Am Med Assoc 2002; 288: 321-333.
3. Cushman MKL, Prentice R, Rodabough RJ, et al.; Women's Health Initiative Investigators. Estrogen plus progestin and risk of venous thrombosis. J Am Med Assoc 2004; 292: 1573-1580.
4. Lowe G, Woodward M, Vessey M, et al. Thrombotic variables and risk of idiopathic venous thromboembolism in women aged 45-64 years. Relationships to Hormone Replacement Therapy. Thromb Haemost 2000; 83: 530-535.
5. Sidelman JJ, Jespersen J, Andersen LF, et al. Hormone replacement therapy and hypercoagulability. Results from the Prospective Danish Climacteric Study. Br J Obstet Gynecol 2003; 110: 541-547.
6. Post MS, Christella LGD, Thomassen MJ, et al. Effect of oral and transdermal estrogen replacement therapy on hemostatic variables associated with venous thrombosis. A randomised controlled study in post menopausal women. Arterioscler Thromb Vasc Biol 2003; 23: 1116-1121.
7. Poulter NR, Chang CL, Farley TMM. Venous thromboembolic disease and combined oral contraceptives: results of an international multicentre case control study. World Health Organisation Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 1995; 346: 1575-1582.
8. Canonico M, Oger E, Plu-Bureau G, et al. Hormone therapy and venous thromboembolism among post menopausal women: impact of the route of Estrogen administration and Progestogens: The ESTHER study. Circulation 2007; 115: 840-845.
9. Brosnan, JF, Sheppard BL, Norris LA. Haemostatic activation in post menopausal women taking low dose hormone therapy: less effect with transdermal administration? Thromb Haemost 2007; 97: 558-565.
10. Gilabert J, Estelles A, Cano A, et al. The effect of oestrogen replacement therapy with or without progesterone on the fibrinolytic system and coagulation inhibitors in postmenopausal status. Am J Obstet Gynecol 1995; 173: 1849-1854.
11. Teede HJ, McGrath BP, Smolich JJ, et al. Post menopausal hormone replacement therapy increases coagulation activity and fibrinolysis. Arterioscler Thromb Vasc Biol 2000; 20: 1404-1409.
12. van Baal WM, Emeis JJ, van der Mooren MJ, et al. Impaired procoagulant-anticoagulant balance during hormone replacement therapy? A randomised, placebo controlled 12 week study. Thromb Haemost 2000; 83: 29-34.
13. Winneker RC, Bitran D, Zhang Z. The pre-clinical biology of a new porent and selective progestin: trimegestone. Steroids 2003; 68: 915-920.
14. Lowe GDO, Rumley A, Woodward M, et al. Epidemiology of coagulation factors, inhibitors and activation markers. The Third Glasgow MONICA Survey.
15. Post MS, Christella LGD, Thomassen MJ, et al. Effect of oral and transdermal estrogen replacement therapy on hemostatic variables associated with venous thrombosis. A randomised controlled study in post menopausal women. Arterioscler Thromb Vasc Biol 2003; 23: 1116-1121.
16. Poulter NR, Chang CL, Farley TMM. Venous thromboembolic disease and combined oral contraceptives: results of an international multicentre case control study. World Health Organisation Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 1995; 346: 1575-1582.
17. Canonico M, Oger E, Plu-Bureau G, et al. Hormone therapy and venous thromboembolism among post menopausal women: impact of the route of Estrogen administration and Progestogens: The ESTHER study. Circulation 2007; 115: 840-845.
18. Brosnan, JF, Sheppard BL, Norris LA. Haemostatic activation in post menopausal women taking low dose hormone therapy: less effect with transdermal administration? Thromb Haemost 2007; 97: 558-565.
19. Gilabert J, Estelles A, Cano A, et al. The effect of oestrogen replacement therapy with or without progesterone on the fibrinolytic system and coagulation inhibitors in postmenopausal status. Am J Obstet Gynecol 1995; 173: 1849-1854.
20. Teede HJ, McGrath BP, Smolich JJ, et al. Post menopausal hormone replacement therapy increases coagulation activity and fibrinolysis. Arterioscler Thromb Vasc Biol 2000; 20: 1404-1409.
21. van Baal WM, Emeis JJ, van der Mooren MJ, et al. Impaired procoagulant-anticoagulant balance during hormone replacement therapy? A randomised, placebo controlled 12 week study. Thromb Haemost 2000; 83: 29-34.
22. Winneker RC, Bitran D, Zhang Z. The pre-clinical biology of a new porent and selective progestin: trimegestone. Steroids 2003; 68: 915-920.
23. Lowe GDO, Rumley A, Woodward M, et al. Epidemiology of coagulation factors, inhibitors and activation markers. The Third Glasgow MONICA Survey. I. Illustrative reference ranges by age sex and hormone use. Br J Haematol 1997; 97: 775-784.
24. Caine YG, Bauer KA, Barzegar S, et al. Coagulation activation following estrogen administration to postmenopausal women. Thromb Haemost 1992; 68: 392-395.
25. Kroon U-B, Silverstone G, Tengborn L. The effects of transdermal estradiol and oral conjugated oestrogens on haemostasis variables. Thromb Haemost 1994; 71: 420-423.
26. Bruge JM, Tans G, Rosing J, et al. Protein S levels modulate the activated protein C resistance induced by elevated prothrombin levels. Thromb Haemost 2006; 95: 236-242.
27. De Visser MCH, Rosendaal FR, Bertina RM. A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis Blood 1999; 93: 1271-1276.
28. Post MS, Rosing J, van der Mooren MJ, et al. Increased resistance to activated protein C after short term oral hormone replacement therapy in healthy post menopausal women. Br J Haematol 2002; 119: 1017-1023.
29. Høibraten E, Quigstad E, Anderson TO, et al. The effects of HRT on haemostatic variables in women with previous venous thromboembolism: results from a randomised double blind clinical trial. Thromb Haemost 2001; 85: 775-781.
30. Kemmeren JM, Algra A, Meijers JC, et al. Effect of second and third generation oral contraceptives on protein C system in the absence or presence of the Factor V Leiden mutation: a randomised trial. Blood 2004; 103: 927-933.
31. Bloemenkamp KW, Rosendaal FR, Helmerhorst FM, et al. Enhancement by factor V Leiden of the risk of deep vein thrombosis associated with oral contraceptives containing third generation progestogens. Lancet 1995; 346: 1593-1596.
32. Lopez Y, Poloma MJ, Rifon J, et al. Measurement of prethrombotic markers in the assessment of acquired hypercoagulable states. Thromb Res 1999; 93: 71-78.
33. Scarabin PY, Alhenc-Gelas M, Plu-Bureau G, et al. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women: A randomised controlled trial. Arterioscler Thromb Biol 1997; 11: 3071-3078.
34. Sgarabotto M, Baldini, M, Dei Cas A, et al. Effects of raloxifene and continuous combined hormone therapy on haemostasis variables: a muticentre randomised double blind study. Thromb Res 2007; 119: 85-91.
35. Stevenson JC, Oladipo, A, Manassiev N, et al. Randomised trial of effect of transdermal continuous combined hormone replacement therapy on cardiovascular risk markers. Br J Haematol 2004; 124: 802-808.
36. Wells MJ, Sheffield WP, Blajchman MA. The clearance of thrombin-antithrombin and related serpinenzyme complexes from the circulation: role of various hepatocyte receptors. Thromb Haemost 1999; 81: 325-337.
37. Cofrancesco E, Cortellaro M, Corradi A, et al. Coagulation activation markers in the prediction of venous thrombosis after elective hip surgery. Thromb Haemost 1997; 77: 267-269.
38. Madsen JS, Kristensen SR, Gram J, et al Positive impact of hormone replacement therapy on the fibrinolytic system: a long term randomised controlled study in healthy post menopausal women. J Thromb Haemost 2002; 1: 1984-1991.
39. Lansink M, Jong M, Bijsterbosch M, et al. Increased clearance explains lower plasma levels of tissue-type plasminogen activator by estradiol. Evidence for potently enhanced mannose receptor. Blood 1999; 94: 1330-1336.
40. Scarabin PY, Vissac A-M, Kirzin JM, et al. Elevated plasma fibrinogen and increased fibrin turnover among healthy women who both smoke and use low dose oral contraceptives. Thromb Haemost 1999; 82: 1112-1116.
41. Simon T, Beau Yon de Jonage-Canonico M, Oger, E, et al. Indicators of lifetime estrogen exposure and the risk of venous thromboembolism. J Thromb Haemost 2006; 1: 71-76.